CLINICAL AND THERAPEUTIC REGULATION: LEGAL FRAMEWORK AND JUDICIAL INTERPRETATION

1. INTRODUCTION

Clinical and Therapeutic Regulation refers to the legal framework governing the research, development, clinical testing, approval, prescription, administration, and monitoring of medical treatments and therapeutic products.

It covers pharmaceuticals, vaccines, biological products, gene therapies, cell-based treatments, regenerative medicine, and other advanced medical interventions.

The principal objective is to ensure that therapeutic products are scientifically evaluated, clinically safe, ethically administered, and supported by adequate evidence of efficacy.

Clinical and therapeutic regulation also protects patients against unauthorised experimentation, misleading medical claims, unsafe treatment practices, and inadequate disclosure of treatment-related risks.

2. LEGAL AND REGULATORY FRAMEWORK IN INDIA

A. DRUGS AND COSMETICS ACT, 1940

This legislation establishes the statutory framework for regulating drugs and applicable biological products. It governs manufacturing, importation, distribution, quality, and regulatory control.

B. NEW DRUGS AND CLINICAL TRIALS RULES, 2019

These Rules regulate clinical trials, investigational new drugs, ethics committees, and clinical-trial permissions.

Important provisions include:

Rule 19: Permission and requirements for conducting clinical trials.

Rule 25: Conditions governing permission for clinical trials.

Rule 39: Medical management and compensation in cases of clinical-trial injury or death.

Rule 40: Compensation-related requirements and determination under the applicable regulatory framework.

C. MEDICAL ETHICS REGULATION

The National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, issued by ICMR, provide important ethical standards.

They emphasise informed consent, patient autonomy, confidentiality, scientific validity, and protection of vulnerable participants.

D. CENTRAL DRUGS STANDARD CONTROL ORGANISATION

CDSCO regulates applicable clinical investigations and therapeutic products through the Central Licensing Authority.

Its functions include examining applications, reviewing clinical evidence, granting regulatory permissions, and monitoring compliance.

E. CONSTITUTIONAL PROTECTION

Articles 14 and 21 of the Constitution protect equality, life, and personal liberty. These provisions are particularly relevant to patient autonomy, access to healthcare, medical accountability, and protection against arbitrary interference with bodily integrity.

3. PRINCIPAL REQUIREMENTS FOR CLINICAL AND THERAPEUTIC APPROVAL

A. SCIENTIFIC VALIDATION

Therapeutic products must be supported by appropriate scientific and clinical evidence demonstrating their quality, safety, and efficacy.

B. ETHICS COMMITTEE APPROVAL

Applicable clinical trials require review and approval by a properly registered Ethics Committee.

C. INFORMED CONSENT

Patients and research participants must receive relevant information concerning the treatment, foreseeable risks, alternatives, and their rights.

D. CLINICAL-TRIAL REGISTRATION

Applicable clinical trials must be registered with the Clinical Trials Registry–India before enrolment of the first participant, in accordance with regulatory requirements.

E. ADVERSE-EVENT REPORTING

Sponsors and investigators must comply with applicable serious adverse-event reporting, investigation, and compensation requirements.

F. POST-MARKETING SURVEILLANCE

Approved therapeutic products remain subject to applicable pharmacovigilance and safety-monitoring obligations.

4. IMPORTANT JUDICIAL DECISIONS AND CASE LAWS

The following decisions establish important direct and analogous principles governing clinical treatment, patient rights, clinical research, and therapeutic accountability.

1. Jacob Puliyel v. Union of India (2022) 7 SCC 339

Authority: Direct – clinical-trial and vaccine regulation.

The Supreme Court examined vaccine safety, clinical-trial transparency, informed public-health decision-making, and adverse-event reporting. It recognised the importance of making relevant clinical-trial findings publicly accessible and facilitating adverse-event reporting while protecting confidentiality.

2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Authority: Direct – informed medical consent.

The Supreme Court explained the requirements of valid consent before medical treatment. It distinguished consent for a particular procedure from consent for additional or materially different procedures. The judgment establishes important protections for patients receiving experimental or advanced therapeutic interventions.

3. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651

Authority: Direct – medical services and consumer protection.

The Supreme Court examined the applicability of consumer protection legislation to medical services. The decision established an important framework for determining when patients may seek consumer remedies for deficient medical services.

4. Parmanand Katara v. Union of India (1989) 4 SCC 286

Authority: Analogous – patient protection and medical responsibility.

The Supreme Court emphasised the obligation to preserve human life and provide necessary medical assistance. The judgment reinforces the importance of patient welfare in clinical treatment and emergency medical situations.

5. Kusum Sharma v. Batra Hospital & Medical Research Centre (2010) 3 SCC 480

Authority: Direct – medical negligence standards.

The Supreme Court discussed the principles governing medical negligence and the standard of care expected from medical professionals. It clarified that an adverse medical outcome does not automatically establish negligence.

6. Common Cause v. Union of India (2018) 5 SCC 1

Authority: Analogous – bodily autonomy and medical decision-making.

The Supreme Court recognised the constitutional significance of individual autonomy and dignity in medical decisions, particularly concerning end-of-life care and advance directives. These principles are relevant to patient autonomy and therapeutic decision-making.

5. LEGAL LIABILITY AND REGULATORY VIOLATIONS

Non-compliance with clinical and therapeutic regulations may result in:

Suspension or cancellation of clinical-trial permissions.

Withdrawal or restriction of therapeutic product approvals.

Civil liability for medical negligence or deficient services.

Compensation for legally established clinical-trial-related injuries.

Criminal liability where the statutory elements of an offence are established.

Disciplinary proceedings against responsible medical professionals.

Regulatory action against manufacturers, sponsors, and research institutions.

Judicial intervention where patient rights or statutory obligations are violated.

6. COMPLIANCE AND GOVERNANCE REQUIREMENTS

Healthcare organisations, pharmaceutical manufacturers, and research institutions should:

Obtain applicable regulatory permissions before conducting clinical trials.

Maintain independent Ethics Committee supervision.

Ensure valid and documented informed consent.

Follow Good Clinical Practice requirements.

Maintain accurate clinical records and research documentation.

Report serious adverse events within prescribed timelines.

Provide legally required medical management and compensation.

Maintain manufacturing quality and product traceability.

Establish pharmacovigilance and patient-grievance mechanisms.

Protect confidential patient and clinical-research information.

7. CONCLUSION

Clinical and Therapeutic Regulation provides the legal foundation for safe, ethical, and scientifically justified medical innovation. It connects pharmaceutical regulation, clinical research, medical ethics, patient autonomy, product quality, and healthcare accountability.

In India, the Drugs and Cosmetics Act, 1940, New Drugs and Clinical Trials Rules, 2019, ICMR ethical guidelines, and constitutional protections collectively establish the principal regulatory framework.

Judicial decisions such as Jacob Puliyel, Samira Kohli, Indian Medical Association, and Kusum Sharma reinforce the importance of informed consent, scientific transparency, patient protection, and professional accountability.

Ultimately, therapeutic innovation must operate within a framework that balances scientific progress with patient safety, ethical research, regulatory transparency, and enforceable legal responsibility.